

Glenmark Pharmaceuticals Launches SUPIROCIN™ (Mupirocin) Antibacterial Cream in Australia, Marking a Milestone in Expansion Strategy

Sydney, 1 June 2024 – Glenmark Pharmaceuticals (Australia) Pty Ltd. (Glenmark), a subsidiary of Glenmark Pharmaceuticals Ltd., a research-based, global pharmaceutical company, is thrilled to announce the much-anticipated launch of SUPIROCIN (Mupirocin) Antibacterial Cream in Australia. This launch signifies Glenmark's foray into the Australian market and serves as a testament to the company's dedication to enhancing healthcare options for consumers across the globe.

The introduction of SUPIROCIN™ (Mupirocin) Antibacterial Cream in Australia is a significant milestone for the company, showcasing Glenmark's investment in this important APAC market. By making SUPIROCIN™ Antibacterial Cream available in Australia, Glenmark is supporting Australian HCPs and Pharmacists offering a choice of mupirocin creams for treating various skin infections. This will help to ensure supply of this important antibacterial cream in a category where having viable alternatives available is important for timely management of skin-based infections given mupirocin is identified by the WHO as an *Essential Anti-Infective* on its Model List of Essential Medicines.

Glenmark's commitment to quality manufacturing processes ensures that SUPIROCIN™ Antibacterial Cream meets the highest standards of efficacy and safety expected by Australian customers.

SUPIROCIN™ (mupirocin) Antibacterial Cream is just the beginning

Glenmark is poised to become a significant contributor to the Australian healthcare sector, with robust plans to expand its local product offerings over the next 18 months. This first launch is a harbinger of many more healthcare solutions that will soon be made available to meet the diverse treatment needs of the Australian population. With a portfolio that focusses on therapeutic areas including dermatology, respiratory and hospital, Glenmark is poised to positively influence the Australian pharmaceutical landscape.

"We are excited to introduce SUPIROCIN™ (mupirocin) Antibacterial Cream to the Australian market, marking the beginning of a fruitful journey with the Australian healthcare community and consumers," said Michael Moffitt, Country Manager, Australia & New Zealand at Glenmark Pharmaceuticals. "This launch is a testament to our dedication to enhancing the healthcare landscape in Australia by providing quality products that offer more choices to healthcare stakeholders."

PBS Information: This product is not listed on the PBS.

Healthcare professionals are requested to refer to the full Product Information before prescribing, available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-01787-1&d=20230817172310101>.

Where to order SUPIROCIN™ (mupirocin) Antibacterial Cream

Glenmark is pleased to partner with Viatris Australia for the distribution of SUPIROCIN™.

For Pharmacies:

For information about ordering – please contact your Viatris Business Advisor or Customer Relations team: 1800 274 276

For Wholesalers:

Viatris will be in contact shortly.

For information about ordering – please contact the Viatris Operations Associate via email on wholesale.cs@viatris.com



About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Script 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. The company has also been Great Place To Work® Certified™ in India for FY 2023. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

Local Media Contact:

Michael Moffitt, Country Manager, Australia & New Zealand
e) Michael.Moffitt@glenmarkpharma.com m) +61 412387087

Global Media Contact:

Udaykumar Murthy, DGM – Corporate Communications
e) corpcomm@glenmarkpharma.com m) [+91-9960377617](tel:+91-9960377617)

INPLMS37720

AU-MUP-2024-00001 (March 2024)